Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1997 1
2008 1
2009 1
2012 4
2013 5
2014 3
2015 2
2016 2
2017 1
2018 1
2019 2
2020 4
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease.
Kosyakovsky J, Fine JM, Frey WH 2nd, Hanson LR. Kosyakovsky J, et al. Pharmaceuticals (Basel). 2021 Jan 27;14(2):95. doi: 10.3390/ph14020095. Pharmaceuticals (Basel). 2021. PMID: 33513737 Free PMC article. Review.
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment for neurodegener …
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present th …
Intranasal administration of CNS therapeutics to awake mice.
Hanson LR, Fine JM, Svitak AL, Faltesek KA. Hanson LR, et al. J Vis Exp. 2013 Apr 8;(74):4440. doi: 10.3791/4440. J Vis Exp. 2013. PMID: 23608783 Free PMC article.
Intranasal administration is a method of delivering therapeutic agents to the central nervous system (CNS). ...Efficacy of therapeutics administered intranasally in this way to mice has been demonstrated in a number of studies including insulin in diabetic mouse mod …
Intranasal administration is a method of delivering therapeutic agents to the central nervous system (CNS). ...Efficacy of therapeuti …
Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement.
Fine JM, Kosyakovsky J, Baillargeon AM, Tokarev JV, Cooner JM, Svitak AL, Faltesek KA, Frey WH 2nd, Hanson LR. Fine JM, et al. Brain Behav. 2020 Mar;10(3):e01536. doi: 10.1002/brb3.1536. Epub 2020 Jan 20. Brain Behav. 2020. PMID: 31960628 Free PMC article.
INTRODUCTION: Intranasal deferoxamine (IN DFO) has been shown to decrease memory loss and have beneficial impacts across several models of neurologic disease and injury, including rodent models of Alzheimer's and Parkinson's disease. METHODS: In order to assess the …
INTRODUCTION: Intranasal deferoxamine (IN DFO) has been shown to decrease memory loss and have beneficial impacts across sever …
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A. Agrawal M, et al. J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24. J Control Release. 2018. PMID: 29772289 Review.
The therapeutic efficacy of the drug is not only affected by its reduced concentration in the brain owing to the existence of blood-brain-barrier (BBB) but also due to its low brain permeability. In this context, the intranasal (IN) route of drug administration has emerged …
The therapeutic efficacy of the drug is not only affected by its reduced concentration in the brain owing to the existence of blood-brain-ba …
Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.
Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd. Hanson LR, et al. Drug Deliv Transl Res. 2012 Jun;2(3):160-8. doi: 10.1007/s13346-011-0050-2. Drug Deliv Transl Res. 2012. PMID: 25786865
The purpose of this study was to both determine concentrations of deferoxamine (DFO), a high-affinity iron chelator, reaching the brains of mice after intranasal administration and to determine its efficacy in a mouse model of spatial memory loss. ...This is the fir …
The purpose of this study was to both determine concentrations of deferoxamine (DFO), a high-affinity iron chelator, reaching the bra …
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Febbraro F, et al. Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24. Exp Neurol. 2013. PMID: 23531432
Hence, we used a Parkinson's disease animal model based on unilateral injection of a recombinant adeno-associated viral vector encoding alpha-synuclein in the rat midbrain. Rats were treated with a novel deferoxamine delivery approach: 6 mg of the compound was administered …
Hence, we used a Parkinson's disease animal model based on unilateral injection of a recombinant adeno-associated viral vector encoding alph …
Intranasal administration of deferoxamine to iron overloaded patients.
Gordon GS, Ambruso DR, Robinson WA, Githens JH. Gordon GS, et al. Am J Med Sci. 1989 May;297(5):280-4. doi: 10.1097/00000441-198905000-00002. Am J Med Sci. 1989. PMID: 2640419
We examined the effect of intranasal administration of deferoxamine on iron excretion in seven patients with iron overload secondary to chronic transfusion therapy. Deferoxamine was administered in doses of 0.75 to 3.0 gm given over 12 hours in a variety of d …
We examined the effect of intranasal administration of deferoxamine on iron excretion in seven patients with iron overload sec …
Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS. Hanson LR, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):679-86. doi: 10.1124/jpet.108.149807. Epub 2009 Jun 9. J Pharmacol Exp Ther. 2009. PMID: 19509317 Free PMC article.
Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload. ...We report here that intranasal administration targets DFO to the brain and reduces systemic exposure, and that intranasal DFO preve …
Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload. ...We re …
Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
Fine JM, Forsberg AC, Stroebel BM, Faltesek KA, Verden DR, Hamel KA, Raney EB, Crow JM, Haase LR, Knutzen KE, Kaczmarczek KD, Frey WH, Hanson LR. Fine JM, et al. J Neurol Sci. 2017 Sep 15;380:164-171. doi: 10.1016/j.jns.2017.07.028. Epub 2017 Jul 21. J Neurol Sci. 2017. PMID: 28870559
Accumulation of metal and the accompanying increase in oxidative stress and inflammation plays an important role in neurodegenerative disease. Deferoxamine (DFO) is a metal chelator found to be beneficial in several animal models of neurodegenerative disease and insult inc …
Accumulation of metal and the accompanying increase in oxidative stress and inflammation plays an important role in neurodegenerative diseas …
Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.
Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, Conway PM, Stroebel BM, Frey WH 2nd, Hanson LR. Fine JM, et al. Neurosci Lett. 2015 Jan 1;584:362-7. doi: 10.1016/j.neulet.2014.11.013. Epub 2014 Nov 13. Neurosci Lett. 2015. PMID: 25445365
Metal chelators have been explored as a less well known approach to treatment. One chelator currently being developed is deferoxamine (DFO), administered via the intranasal (IN) route. In the current study, APP/PS1 amyloid mice were treated with a chronic, low dose …
Metal chelators have been explored as a less well known approach to treatment. One chelator currently being developed is deferoxamine …
27 results